Xvivo Perfusion AB (OSTO:XVIVO) COGS-to-Revenue : 0.27 (As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is Xvivo Perfusion AB COGS-to-Revenue?

Xvivo Perfusion AB's Cost of Goods Sold for the three months ended in Mar. 2025 was kr58.2 Mil. Its Revenue for the three months ended in Mar. 2025 was kr218.6 Mil.

Xvivo Perfusion AB's COGS to Revenue for the three months ended in Mar. 2025 was 0.27.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Xvivo Perfusion AB's Gross Margin % for the three months ended in Mar. 2025 was 73.37%.

Xvivo Perfusion AB COGS-to-Revenue Historical Data

The historical data trend for Xvivo Perfusion AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB COGS-to-Revenue Chart

Xvivo Perfusion AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.28

0.27

0.28

0.26

0.25

Xvivo Perfusion AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.27	0.25	0.25	0.23	0.27

Xvivo Perfusion AB COGS-to-Revenue Calculation

Xvivo Perfusion AB's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	206	/	822.415
	=	0.25

Xvivo Perfusion AB's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	58.214	/	218.588
	=	0.27

Xvivo Perfusion AB (OSTO:XVIVO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Xvivo Perfusion AB's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	58.214 / 218.588
	=	73.37 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Xvivo Perfusion AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Xvivo Perfusion AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OSTO:XVIVO) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

XVIPF:USA XVIVOs:UK 0RKL:UK 3XV:Germany

Address

Gemenskapens gata 9, Molndal, SWE, SE-431 53

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all of the majority organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines